- Open Access
Mutants in the lipopolysaccharide of Brucella ovis are attenuated and protect against B. ovis infection in mice
© Soler-LLoréns et al.; licensee BioMed Central Ltd. 2014
- Received: 23 January 2014
- Accepted: 13 June 2014
- Published: 17 July 2014
Brucella spp. are Gram-negative bacteria that behave as facultative intracellular parasites of a variety of mammals. This genus includes smooth (S) and rough (R) species that carry S and R lipopolysaccharides (LPS), respectively. S-LPS is a virulence factor, and mutants affected in the S-LPS O-polysaccharide (R mutants), core oligosaccharide or both show attenuation. However, B. ovis is naturally R and is virulent in sheep. We studied the role of B. ovis LPS in virulence by mutating the orthologues of wadA, wadB and wadC, three genes known to encode LPS core glycosyltransferases in S brucellae. When mapped with antibodies to outer membrane proteins (Omps) and R-LPS, wadB and wadC mutants displayed defects in LPS structure and outer membrane topology but inactivation of wadA had little or no effect. Consistent with these observations, the wadB and wadC but not the wadA mutants were attenuated in mice. When tested as vaccines, the wadB and wadC mutants protected mice against B. ovis challenge. The results demonstrate that the LPS core is a structure essential for survival in vivo not only of S brucellae but also of a naturally R Brucella pathogenic species, and they confirm our previous hypothesis that the Brucella LPS core is a target for vaccine development. Since vaccine B. melitensis Rev 1 is S and thus interferes in serological testing for S brucellae, wadB mutant represents a candidate vaccine to be evaluated against B. ovis infection of sheep suitable for areas free of B. melitensis.
- Mutant Strain
- Parental Strain
- Core Defect
- Mutator Plasmid
Brucellosis is a worldwide extended infectious disease caused by the Gram-negative bacteria of the genus Brucella. This genus includes several species among which B. abortus preferentially infects cattle, B. suis swine and wild-life and B. melitensis goats and sheep. These three species are zoonotic and cause a grave and debilitating disease in humans. Sheep can also be infected by B. ovis, a non-zoonotic species. B. ovis brucellosis is characterized by a decreased fertility in rams, occasional abortions and a rise in perinatal mortality [,]. These four Brucella species differ not only in host range and pathogenicity but also in surface characteristics. Whereas B. abortus, B. melitensis and B. suis carry a smooth (S) type lipopolysaccharide (LPS) in the outer membrane, B. ovis LPS lacks the O-polysaccharide typical of S-LPS and thus resembles in this feature the rough (R) LPS mutants of S brucellae [].
Sheep brucellosis caused by either B. melitensis or B. ovis can be controlled by vaccination with the attenuated strain B. melitensis Rev 1 and, in fact, this is the only effective way to control sheep brucellosis in areas with a high or moderate prevalence of the disease []. However, Rev 1 has several drawbacks: it causes an antibody response interfering with the serological diagnosis of B. melitensis, is virulent in humans and resistant to streptomycin, an antibiotic of choice for brucellosis treatment []. Therefore, Rev 1 is forbidden in countries where B. melitensis has been eradicated [], which leads to the increase of B. ovis infections in sheep. Thus, research on B. ovis-specific vaccines is an area of intense research [–]. Acellular vaccines can be an alternative, and attempts have been carried out with whole cell and subcellular extracts [], recombinant proteins [] or DNA vaccines []. However, these strategies usually require boosters and adjuvants or immune modulators to reach an adequate Th1 response [,], with the ensuing increase in costs and difficulties of implementation in extensively bred sheep.
The purpose of the research reported here was twofold: to study the involvement of LPS in B. ovis virulence and to develop B. ovis-specific vaccine candidates that could overcome the above-summarized drawbacks. To this end, we built on previous genetic analyses that have shown that at least three glycosyltransferases (wadA, wadB and wadC) are necessary for the complete assembly of the core oligosaccharide of B. abortus and B. melitensis [,,,].
Bacterial strains and growth conditions
Bacterial strains and plasmids used in this work
virulent strain, natural NalR
PA in frame deletion mutant in wadA Δ58-679
PA in frame deletion mutant in wadB Δ49-195
PA in frame deletion mutant in wadC Δ17-306
challenge strain, PA GmR
mating strain with plasmid RP4 inserted into the chromosome
Simon et al. []
F−lacI q Tn 10 (TetR) mcrA Δ(mrr-hsdRMS-mcrBC) 80lacZ ΔM15 ΔlacX74 recA1alaD139 endA1 nupG
derivated of pJQ200KS+; KmR, GmS
Scupham and Triplett []
913-bp of B. abortus parental chromosomal DNA containing the wadA deletion allele, generated by PCR and cloned into pCR2.1
BamHI-XbaI fragment from pYRI-12 cloned into the corresponding sites of pJQK
570-bp of B. abortus parental chromosomal DNA containing the wadB deletion allele, generated by PCR and cloned into pCR2.1
Gil-Ramírez et al. []
BamHI-XbaI fragment from pYRI-1 cloned into the corresponding sites of pJQK
Gil-Ramírez et al. []
934-bp of B. ovis parental chromosomal DNA containing the wadC deletion allele, generated by PCR and cloned into pCR2.1
BamHI-XbaI fragment from pYRI-14 cloned into the corresponding sites of pJQK
DNA manipulations and sequence analyses
Plasmid and genomic DNA were isolated with Qiaprep Miniprep (Qiagen GmbH, Hilden, Germany) and Ultraclean Microbial DNA Isolation Kit (MoBio Laboratories, Carlsbad, CA, USA), respectively. When needed, DNA was also purified from agarose gels using a Qiack Gel extraction kit (Qiagen). DNA sequencing was performed by the dideoxy method at the Sequencing Unit of Centro de Investigación Médica Aplicada (CIMA, Universidad de Navarra, Spain), and primers were synthesized by Sigma-Aldrich Ltd. Searches for DNA and protein homologies were carried out using the Kyoto Encyclopedia of Genes and Genomes [], EMBL-European Bioinformatics Institute server [] and National Center for Biotechnology Information (NCBI) database [].
Construction of LPS mutants
Primers used in the study
Sequence (5’-- > 3’)
CCC ACG CTG CTT AGT ACG TT
CAT CAA AAC GTG CAT CGT CAA
ATT GAC GAT GCA CGT TTT GAT GCA TTC GGC TTT GCC TTT TAT
GAG TTT ATC GCC CAA TTT GC
TCT TCC AGA ATG AGG CCG TA
GCA TGA TTA CCC CGC TGAT
CGC AAT CTC GTC TTT GTT GAG
CTC AAC AAA GAC GAG ATT GCG GGT GGC GTG AAG GAA ATCT
TGA TAG CCG AGC CTC TTC AG
ATG CAC CCA TGA AGT TTT CC
CTG GCG TCA GCA ATC AGA G
GTG CAA CGA CCT CAA CTT CC
GGA AGT TGA GGT CGT TGC ACA CGC CAT CGA ACC TTA TCT G
CGG CTA TCG TGC GAT TCT
GCA ATG GAA TGA GCT GAA CA
The ΔwadA mutant (BOV_0614) was obtained in a similar way. Briefly, primers wadA-F1 and wadA-R2 were used to amplify a 453-bp fragment including codon 1 to 57 of the 5′end of wadA (BOV_0614), as well as 284-bp upstream of the wadA start codon; and primers wadA-F3 and wadA-R4 were used to amplify a 460-bp fragment including codons 680 to 704 of the wadA ORF and 386-bp downstream of the wadA stop codon. Both fragments were ligated by overlapping PCR using primers wadA-F1 and wadA-R4, the resulting fragment was cloned into pCR2.1, sequenced and subcloned into pJQK. The resulting mutator plasmid (pYRI-13, Table 1) was introduced in B. ovis PA by electroporation with a micropulser (Bio-Rad, Hercules, CA, USA) as described before []. The first recombination event was selected by Km resistance, and the second by sucrose resistance and Km sensitivity. The resulting colonies were screened by PCR with primers wadA-F1 and wadA-R4, which amplify a fragment of 913-bp in the mutant strain and a fragment of 2782-bp in the parental strain. An additional PCR was carried out to exclude the presence of the complete gene. The amplification was done with primers wadA-F1 and wadA-R5, which include a fragment from the deleted region of the gene. While strains carrying the complete gene amplified a 565-bp fragment, no amplification was obtained with the mutant strain (see Additional file 1). The deletion was confirmed by sequencing. As a result of the mutation 82% of the wadA ORF was lost and the mutant strain was called BoΔwadA (Table 1).
Taking into account that the wadB sequence of B. abortus 2308 and B. ovis PA are almost identical (99.86% homology with only one base pair change in the deleted section of the gene), we used the mutator plasmid pYRI-2 (Table 1) that was previously constructed to generate ΔwadB (BAB1_0351) mutants in B. abortus 2308 for the construction of the B. ovis ΔwadB mutant []. The mutator plasmid pYRI-2 was introduced in B. ovis PA by conjugation. The resulting colonies were screened by PCR with primers wadB-F1 and wadB-R4, which amplify a fragment of 570-bp in the mutant strain and a fragment of 1011-bp in the parental strain. An additional PCR was carried out to exclude the presence of the complete gene. The amplification was done with primers wadB-F1 and wadB-R5, which include a fragment from the deleted region of the gene. While strains carrying the complete gene amplified a 471-bp fragment, the mutant strain was unable to amplify the fragment (Additional file 1). The deletion was confirmed by sequencing. As a result of the mutation 60% of the wadB ORF was lost, and the mutant strain was called BoΔwadB (Table 1).
In all mutagenesis experiments, after the second recombination, two type of colonies Nal and sucrose resistant and Km sensitive could be isolated: the deletion mutant strain and the strain that had reverted to the wild-type genotype (hereafter “sibling revertant strain”). The latter was also selected as control for additional mutations elsewhere in the chromosome that may have been acquired during the manipulations described above, and the genotypes of all the strains were confirmed by PCR amplification and sequencing of the target locus in the genome. Moreover, both mutant and sibling revertant strains were characterized following standard Brucella typing procedures [], and purity checked by inhibition of growth on BAB-S supplemented with Km.
LPS extraction and characterization
Extraction of whole-cell LPS by SDS-proteinase K protocol was performed as described by Dubray and Limet [] with modifications. Briefly, heat inactivated cells were suspended in 0.0625 M Tris–HCl buffer (pH 6.8) containing 2% SDS (wt/wt). Samples were heated at 100 °C for 10 min, and the lysates were tempered to 55 °C and digested twice with proteinase K (10 mg/mL, one hour at 55 °C). After that, samples were kept overnight at 20 °C and then stored at −20 °C. LPS were analysed in Tris-Tricine-HCl-glycine poliacrilamyde gel electrophoresis (Tricine SDS-PAGE) as described by Lesse []. Briefly, a 16 × 20 cm two-phase gel (18% acrylamide-bisacrylamide for the running gel and 4% for the stacking gel) was prepared in 1 M Tris 0.1% SDS, pH 8.45. The gel was placed between anode and cathode buffers (0.2 M Tris–HCl pH 8.9 and 0.2 M Tris–HCl, 0.1 M Tricine, 0.1% SDS pH 8.45, respectively) and the electrophoresis was carried out at constant voltage for one h at 30 V followed by 20 h at 70 V. LPS was stained by the periodate-alkaline silver method []. For Western blots, LPS was electrotransferred onto nitrocellulose membranes, blocked with 1% skimmed milk in PBS for 45 min and incubated with specific monoclonal antibodies (MAbs, see below) overnight. After washing, bound immunoglobulins were detected by chemiluminiscence (Thermo Fisher Scientific Inc., Waltham, USA) with goat anti mouse IgG (H + L) chain specific B. ovis conjugate secondary antibodies (Merk4Biosciencies, Damstadt, Germany).
Surface topology mapping
Outer membrane proteins (Omp) and LPS exposure on the cell surface was assessed by ELISA with the following MAbs: A76/08C03/G03 for Omp16, A76/05C10/A08 for Omp19, A68/25G05/A05, A68/15B06/C08 and A63/04D11/G01 for Omp2b, A59/05F01/C09 for Omp25, A59/10F09/G10 for Omp31, and A68/24G12/A08, A68/24D08/G09 and A68/10A06/B11 for R-LPS [–]. ELISA using whole bacteria as the antigen were performed as described previously [,] with some modifications. Briefly, lyophilized bacteria were resuspended up to OD600 1 in phosphate-buffered saline pH 7.4 (PBS). For coating, this suspension was distributed (100 μL/well) in 96 flat bottom plates (Thermo Scientific) and incubated overnight at room temperature. One-hundred microliters of MAbs (hybridoma supernatant diluted 1:3 in 0.05% Tween PBS) were incubated 37 °C for 1 h. Bound MAbs were then detected with an affinity-purified goat anti-mouse immunoglobulin G (H + L chains) – horseradish peroxidase conjugate (Bio-Rad, Hercules, CA, USA) (diluted 1:6000 in 0.05% Tween PBS) incubated for 1 h at room temperature. Between all the previous steps five washes with 250 μL 0.05% Tween PBS were performed in order to eliminate the excess of MAbs and conjugate. Enzyme activity was revealed by the addition of TMB ELISA peroxidase substrate (Interchim, Montlucon, France) and stopped after 20 min at room temperature with 1 M HCl based stop solution (Interchim). Plates were read at 450 nm with a microplate reader (Thermo Fisher Scientific Inc.).
Physico-chemical surface properties
Autoagglutination capacity was evaluated by measuring the OD600 evolution of a bacterial suspension in TSB-YE-S, over 48 h of static incubation at room temperature, starting from initial readings of 0.8 (100% OD600) in TSB-YE-S []. The results were represented as the mean ± SD of the values obtained for three assays at each time point, in three independent assays. The surface charge density was measured as the electrophoretically effective potential (Zeta potential) []. For this, bacteria were inactivated with 0.5% phenol, washed and resuspended in 0.1 M KCl, 10 mM HEPES 10 mM (pH 7.2) at an OD600 of 0.1. Measurements were performed at 25 °C in a Zetamaster instrument using the PCS 1.27 software (Malvern Instruments Ltd., Malvern, UK) and the settings of aqueous solutions (viscosity = 1.002 cP; dielectric constant = 80.4), in plain buffer.
Susceptibility to nonimmune serum and polymyxin B
Sensitivity to the bactericidal action of nonimmune serum was determined as follows: exponentially growing bacteria were adjusted to 2 × 104 CFU/mL in PBS and dispensed in microtiter plates (50 μL/well) containing fresh normal calf serum or serum previously heated at 56 °C for 60 min to remove complement (150 μL/well). After incubation for 3 h at 37 °C, 50 μL of each sample was plated TSA-YE-S by triplicate, and the results are expressed as the proportion between the organism cultivable after exposure to normal nonimmune serum and those cultivable after the exposure to serum in which complement had been heat inactivated. Sensitivity to polymyxin B (Sigma-Aldrich Ltd.) was determined as described before [].
Virulence and vaccine efficacy studies in mice
Female 8–10 week-old BALB/c mice (Charles River International, France) were used. They were randomly distributed and accommodated in the animal facilities of Universidad Pública de Navarra (registration code ES/31-2016-000002 CR-SU-US) for 1–2 weeks before starting and during the assays, with water and food ad libitum. The procedures performed with mice were designed according to national (RD 53/2013) and European (EU directive 2010/63) legislations regarding the use of animals in research. Mice inoculations were carried out with 0.1 mL of bacterial suspensions previously adjusted to an OD600 of 0.170 (around 1 × 109 CFU/mL) and then diluted to the appropriate dose (see below) in sterile PBS []. Exact inoculation doses were determined retrospectively by plating tenfold dilutions prepared in PBS on BAB-S or TSA-YE-S.
For virulence, BALB/c mice (n = 10) were inoculated intraperitoneally (IP) with 5–7 × 105 CFU/mouse of the corresponding B. ovis PA mutant strain, and viable spleen counts were determined (n = 5) at 3 and 10 weeks post-inoculation as previously detailed []. As a control, additional groups of mice (n = 10) were inoculated similarly with the virulent B. ovis PA reference or the sibling reverting strains, to control for the potential for incidental attenuation during the manipulation required for mutagenesis. The identity of the spleen isolates was confirmed throughout the experiment by both PCR and B. ovis phenotypic features []. Spleen infections were expressed as mean ± SD (n = 5) of individual log10 CFU/spleen at the times indicated [].
Efficacy of the BoΔwadB and BoΔwadC mutants as vaccines was evaluated in BALB/c mice (n = 10) vaccinated intraperitoneally with 1 × 108 CFU/mouse of the corresponding B. ovis mutant strain, or subcutaneously (SC) with 1 × 105 CFU/mouse of B. melitensis Rev 1 (as standard vaccinated control), or with 0.1 mL of PBS (pH 6.8) as the unvaccinated control. Four weeks after vaccination, all mice were challenged intraperitoneally with 5 × 105 CFU/mouse of the virulent B. ovis PA-GmR (Table 1), and the number of challenge bacteria in spleens was determined 3 weeks afterwards []. Differentiation between challenge and residual vaccine bacteria was performed by duplicate plating on BAB-S and BAB-S supplemented with Gm. Results are expressed as the mean and SD (n = 10) of the individual log10 CFU/spleen of B. ovis PA-GmR challenge strain. Statistical comparisons of mean log10 CFU/spleen were performed by a one-way ANOVA followed by the Fisher’s Protected Least Significant Differences tests []. The virulence of the B. ovis PA-GmR challenge strain used in this work was proved in a previous experiment in BALB/c mice (n = 5) by intraperitoneal infection (5 × 105 CFU/mouse) and bacterial spleen counting at 3 weeks later. This strain showed identical bacterial counts in BAB-S and BAB-S supplemented with Gm, and identical multiplication to that of B. ovis PA in mice (not shown).
Construction of B. ovis LPS mutants
Several ORF encoding putative glycosyltransferases have been shown to be involved in the biosynthesis of the core of B. abortus LPS: wadA (formerly named wa**, BAB1_0639, [,]), wadB (BAB1_0351, [,]) and wadC (BAB1_1522, [,]). We searched for orthologues of these glycosyltransferases in the B. ovis strain ATCC25840 genome sequence and we identified three ORF: BOV_0614 for wadA, BOV_0337 for wadB and BOV_1453 for wadC, with 99.4%, 99.9% and 100% DNA sequence identity, respectively. Non-polar mutant and sibling revertant strains were obtained for each target gene from B. ovis PA strain as described in the Materials and methods section. PCR amplification and sequencing of the target loci in the genome of the mutants confirmed inactivation of the respective genes (data not shown). All mutants behaved like the parental strain in classical bacteriological typing for the genus Brucella [] and showed no differences in growth patterns when compared to the parental strain B. ovis PA (data not shown).
B. ovis wadB and wadC are required for the synthesis of a complete LPS
LPS gene mutants of B. ovis have altered key topological, physicochemical and biological surface properties
Both BoΔwadB and BoΔwadC mutants are attenuated and protect against B. ovis PA infection in mice
Colonization of B. ovis PA and the LPS mutant strains in mouse spleens
log10CFU in spleen
3 weeks post infection
10 weeks post infection
mean ± SD
mean ± SD
B. ovis PA
6.56 ± 0.52
4.67 ± 0.86
6.78 ± 0.40
4.41 ± 2.01
2.31 ± 1.91a
0.80 ± 0.42a
3.82 ± 0.72a
1.11 ± 0.77a
5.89 ± 0.77
4.90 ± 0.45
6.49 ± 0.23
4.71 ± 1.68
Efficacy of B. ovis LPS mutants in BALB/c mice against a virulent B. ovis infection
Log10CFU in spleen (mean ± SD)
No. of non-infected/ total mice studied
1.08 ± 1.22a,c
2.18 ± 1.59a
B. melitensis Rev 1 (105/SC)
2.75 ± 1.26b
PBS (unvaccinated control)
6.24 ± 0.48c
Several differences have been shown in the structure of the LPS among the different species of the genus Brucella [–]. Wild-type B. melitensis, B. abortus, B. suis, B. neotomae, B. ceti, B. pinnipedialis and B. microti produce a S-LPS where the O-polysaccharide is linked to the core oligosaccharide. However, B. ovis and B. canis lack this O-polysaccharide thus producing an R-LPS. The genetic bases of this R phenotype have been partially described []. In B. ovis, the genome shows a 15 Kb deletion which includes genes wboA and wboB [,], both involved in the synthesis of the O-polysaccharide, and several point mutations generating nonfunctional proteins, wbkF and wzt among others [], involved in bactoprenol priming (see also below) and export of the O-polysaccharide to the periplasm, respectively.
The structures of the core and repeated O-polysaccharide fragments of B. abortus biovar 4, B. melitensis biovar 3 and B. suis biovar 4 obtained after acid hydrolysis of S-LPS have been recently published []. The structure available for the core oligosaccharide (Figure 1) shows the existence of a side oligosaccharide chain composed of four residues of glucosamine, plus glucose and mannose, the latter linked to Kdo I, with Kdo II linked to another glucose from which the O-polysaccharide stems. Although the precise structure of LPS of B. ovis remains to be determined, a previous immunochemical assay carried out with R-LPS extracted from B. ovis REO198 found fragments that were estimated to contain 2, 4, 6 and 7 sugars, including glucose, mannose, glucosamine, Kdo and an unidentified sugar []. Up to now only three glycosyltransferases have been shown to be involved in the synthesis of the LPS core in B. abortus and B. melitensis (wadA, wadB and wadC), and B. ovis carries the corresponding orthologous ORF. Although the homology of these glycosyltransferases suggests that the composition of B. ovis core LPS is similar to other Brucella species, antigenic and immunochemical analyses of LPS extracts have showed differences [,].
In B. abortus and B. melitensis, the deletion of wadA results in an R phenotype and an altered LPS core [,]. In B. melitensis, the wadA mutant carries a defective LPS core but also synthesizes a free cytoplasmic O-polysaccharide, which strongly suggests that wadA codes for a glycosyltransferase involved in the synthesis of the core section linked to the O-polysaccharide []. Taking into account previous electrophoretic analysis of the R-LPS, wadA is likely to encode the enzyme involved in transferring the glucose linked to quinovosamine [] (Figure 1). In the case of B. ovis, the reactivity with MAbs, the cell surface properties, the electrophoretic analyses of the LPS and the virulence assays all showed a similar behavior for mutant BoΔwadA and the parental strain. Quinovosamine, absent in B. ovis REO 198 LPS [], is in all likelihood the sugar priming bactoprenol for O-polysaccharide synthesis [], and B. ovis carries mutations in wbkF, involved in bactoprenol priming, so LPS oligosaccharide lacks a terminal glucose in the wadA mutants. Such a small defect would be consistent with the fact that the B. ovis ΔwadA mutant was practically indistinguishable from the parental strain.
Although the LPS core of B. abortus and B. melitensis mutants is altered, the O-polysaccharide remains in place [5–7 and Conde R., Arce-Gorvel V., Iriarte M., Gorvel J.P. and Moriyón I., unpublished results]. This evidence shows that glycosyltransferases WadB and WadC are responsible for the synthesis of the glucosamine rich oligosaccharide stemming from Kdo II (Figure 1). Specifically, it has been proposed that WadC could be implicated in the transfer of the first mannose to the lateral chain, while WadB would transfer other sugar [,]. In B. abortus, both mutants induce a pro-inflammatory response higher than that of wild-type bacteria and are thus attenuated in dendritic cells and mice [–]. Moreover, they are more sensitive to the bactericidal action of the nonimmune serum and cationic peptides [,]. It has also been proved that the core defect enhances recognition by the TLR4-MD2 receptor/co-receptor system and, accordingly, a glucosamine-rich branch of the LPS core of the B. abortus and B. melitensis acts as a shield against recognition by several innate immune systems, thus representing a virulence mechanism of these Brucella spp. []. In B. ovis, the LPS of the mutants ΔwadB and ΔwadC lacks a part of the core oligosaccharide (component I in Figure 2) and the defects generate a marked increase in the negative value of zeta potential that can be explained by the loss of all or part of the positively charged glucosamine residues (Figure 1). The attenuation observed for mutants BoΔwadB and BoΔwadC show for the first time that the LPS of a naturally R Brucella pathogenic species (i.e. B. ovis) is essential for survival in the mouse model. Even though the exact mechanism remains to be elucidated, the proposed core defect is likely to facilitate the recognition of B. ovis LPS by innate immunity. Indeed, this hypothesis is supported by the above-summarized results obtained with the homologous B. abortus and B. melitensis mutants and with the fact that, rather than the O-polysaccharide, it is the lipid A-core overall structure that is recognized by multiple innate immunity systems [–,,]. Nevertheless, other effects cannot be disregarded because the mutants BoΔwadB and BoΔwadC were affected not only in the LPS but also in the topology of the outer membrane as detected with anti-Omp MAbs. Little is known about how these changes may affect the virulence of brucellae but it has been shown that not all the B. melitensis R mutants are equivalent in their surface properties and outer membrane topology, and that they have different levels of interaction with host cells, virulence and vaccination power [,].
Recently, Conde-Álvarez et al. [] proposed a new strategy to develop vaccines against brucellosis based on the concept that the surface molecules of Brucella effectively evade a prompt detection by innate immunity [], and that surface changes such as those introduced by mutations affecting the glucosamine branch of the core would overcome hampered recognition thus producing a protective Th1 response. This concept was based on a comparison of a B. abortus wadC mutant and the current vaccine B. abortus S19 in the mouse model []. Although we have not evaluated the immune response in this work, our results add further weight to the value of this strategy and show the possibility of obtaining vaccines against brucellosis caused by B. ovis that could be used in areas free of B. melitensis. However, a potential defect of these vaccines would be their interference in the diagnosis of B. ovis, which is carried out using tests that detect antibodies to both Omp and R-LPS []. These problems, however, could be circumvented by the use of antigenically-tagged brucellosis vaccines, a strategy recently shown to be effective for the vaccine B. abortus S19 in the mouse model []. Research is in progress to evaluate all these possibilities in sheep.
This work was funded by Ministerio de Economía y Competitividad of Spain (reference project AGL2011-30453-C04) and Fundación para la Investigación Médica Aplicada (FIMA). Financial support to PS-L from Ministerio de Economía y Competitividad of Spain (reference BES-2009-015656), AZ-B from Universidad Pública de Navarra, and BSR from CSIC and European Social Fund (Programa JAE-Doc) are also gratefully acknowledged.
- Burgess GW: Ovine contagious epididymitis: a review. Vet Microbiol. 1982, 7: 551-575. 10.1016/0378-1135(82)90049-9.View ArticlePubMedGoogle Scholar
- Garin-Bastuji B, Blasco JM: Ovine epididymitis. Manual of diagnostic tests and vaccines for Terrestrial Animals (mammals, birds and bees). 2013, World Organization for Animal Health, Paris, FranceGoogle Scholar
- Diaz R, Bosseray N: Idenfification d’un composé antigénique spécifique de la phase rugueuse (R) des Brucella. Ann Vet Res. 1973, 4: 283-292.Google Scholar
- Lapaque N, Moriyon I, Moreno E, Gorvel J-P:Brucella lipopolysaccharide acts as a virulence factor. Curr Opin Microbiol. 2005, 8: 60-66. 10.1016/j.mib.2004.12.003.View ArticlePubMedGoogle Scholar
- Conde-Álvarez R, Arce-Gorvel V, Iriarte M, Manček-Keber M, Barquero-Calvo E, Palacios-Chaves L, Chacón-Díaz C, Chaves-Olarte E, Martirosyan A, von Bargen K, Grilló M-J, Jerala R, Brandenburg K, Llobet E, Bengoechea JA, Moreno E, Moriyón I, Gorvel J-P: The lipopolysaccharide core of Brucella abortus acts as a shield against innate immunity recognition. PLoS Pathog. 2012, 8: e1002675-10.1371/journal.ppat.1002675.PubMed CentralView ArticlePubMedGoogle Scholar
- Conde-Álvarez R, Arce-Gorvel V, Gil-Ramírez Y, Iriarte M, Grilló M-J, Gorvel JP, Moriyón I: Lipopolysaccharide as a target for brucellosis vaccine design. Microb Pathog. 2013, 58: 29-34. 10.1016/j.micpath.2012.11.011.View ArticlePubMedGoogle Scholar
- Gil-Ramírez Y, Conde-Álvarez R, Palacios-Chaves L, Zúñiga-Ripa A, Grilló M-J, Arce-Gorvel V, Hanniffy S, Moriyón I, Iriarte M: The identification of wadB, a new glycosyltransferase gene, confirms the branched structure and the role in virulence of the lipopolysaccharide core of Brucella abortus. Microb Pathog. 2014, 73: 53-59. 10.1016/j.micpath.2014.06.002.View ArticlePubMedGoogle Scholar
- Kubler-Kielb J, Vinogradov E: The study of the core part and non-repeating elements of the O-antigen of Brucella lipopolysaccharide. Carbohydr Res. 2013, 366: 33-37. 10.1016/j.carres.2012.11.004.PubMed CentralView ArticlePubMedGoogle Scholar
- Blasco JM: A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet Med. 1997, 31: 275-283. 10.1016/S0167-5877(96)01110-5.View ArticlePubMedGoogle Scholar
- Da Martins RC, Irache JM, Gamazo C: Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease. Expert Rev Vaccines. 2012, 11: 87-95. 10.1586/erv.11.172.View ArticleGoogle Scholar
- Silva AP, Macêdo AA, Costa LF, Turchetti AP, Bull V, Pessoa MS, Araújo MS, Nascimento EF, Martins-Filho OA, Paixão TA, Santos RL:Brucella ovis lacking a species-specific putative ATP-binding cassette transporter is attenuated but immunogenic in rams. Vet Microbiol. 2013, 167: 546-553. 10.1016/j.vetmic.2013.09.003.View ArticlePubMedGoogle Scholar
- Moriyón I, Grilló MJ, Monreal D, González D, Marín C, López-Goñi I, Mainar-Jaime RC, Moreno E, Blasco JM: Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res. 2004, 35: 1-38. 10.1051/vetres:2003037.View ArticlePubMedGoogle Scholar
- Blasco JM, Gamazo C, Winter AJ, de Bagüés MP J, Marín C, Barberán M, Moriyón I, Alonso-Urmeneta B, Díaz R: Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams. Vet Immunol Immunopathol. 1993, 37: 257-270. 10.1016/0165-2427(93)90198-D.View ArticlePubMedGoogle Scholar
- Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA: A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine. 2007, 25: 4437-4446. 10.1016/j.vaccine.2007.03.028.View ArticlePubMedGoogle Scholar
- Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA: A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine. 2007, 25: 5958-5967. 10.1016/j.vaccine.2007.05.049.View ArticlePubMedGoogle Scholar
- Da Costa MR, Irache JM, Blasco JM, Muñoz MP, Marín CM, Jesús Grilló M, Jesús De Miguel M, Barberán M, Gamazo C: Evaluation of particulate acellular vaccines against Brucella ovis infection in rams. Vaccine. 2010, 28: 3038-3046. 10.1016/j.vaccine.2009.10.073.View ArticleGoogle Scholar
- Monreal D, Grilló MJ, González D, Marín CM, De Miguel MJ, López-Goñi I, Blasco JM, Cloeckaert A, Moriyón I: Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model. Infect Immun. 2003, 71: 3261-3271. 10.1128/IAI.71.6.3261-3271.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- González D, Grilló M-J, De Miguel M-J, Ali T, Arce-Gorvel V, Delrue R-M, Conde-Alvarez R, Muñoz P, López-Goñi I, Iriarte M, Marín C-M, Weintraub A, Widmalm G, Zygmunt M, Letesson J-J, Gorvel J-P, Blasco J-M, Moriyón I: Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS One. 2008, 3: e2760-10.1371/journal.pone.0002760.PubMed CentralView ArticlePubMedGoogle Scholar
- Simon R, Priefer U, Pühler A: A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in gram negative bacteria. Nat Biotechnol. 1983, 1: 784-791. 10.1038/nbt1183-784.View ArticleGoogle Scholar
- Scupham AJ, Triplett EW: Isolation and characterization of the UDP-glucose 4’-epimerase-encoding gene, galE, from Brucella abortus 2308. Gene. 1997, 202: 53-59. 10.1016/S0378-1119(97)00453-8.View ArticlePubMedGoogle Scholar
- ᅟ: Kyoto Encyclopedia of Genes and Genomes.ᅟ ᅟ, ᅟ:ᅟ , [http://www.genome.jp/kegg/]
- ᅟ: EMBL-European Bioinformatics Institute.ᅟ ᅟ, ᅟ:ᅟ , [http://www.ebi.ac.uk]
- ᅟ: National Center for Biotechnology Information.ᅟ ᅟ, ᅟ:ᅟ , [http://www.ncbi.nlm.nih.gov/]
- Caro-Hernández P, Fernández-Lago L, de Miguel M-J, Martín-Martín AI, Cloeckaert A, Grilló M-J, Vizcaíno N: Role of the Omp25/Omp31 family in outer membrane properties and virulence of Brucella ovis. Infect Immun. 2007, 75: 4050-4061. 10.1128/IAI.00486-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Alton GG: Techniques for the Brucellosis Laboratory. 1987, Institut National de la Recherche Agronomique (INRA), Paris, FranceGoogle Scholar
- Dubray G, Limet J: Evidence of heterogeneity of lipopolysaccharides among Brucella biovars in relation to A and M specificities. Ann Inst Pasteur Microbiol. 1987, 138: 27-37. 10.1016/0769-2609(87)90051-2.View ArticlePubMedGoogle Scholar
- Lesse AJ, Campagnari AA, Bittner WE, Apicella MA: Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. J Immunol Methods. 1990, 126: 109-117. 10.1016/0022-1759(90)90018-Q.View ArticlePubMedGoogle Scholar
- Tsai CM, Frasch CE: A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem. 1982, 119: 115-119. 10.1016/0003-2697(82)90673-X.View ArticlePubMedGoogle Scholar
- Bowden RA, Cloeckaert A, Zygmunt MS, Bernard S, Dubray G: Surface exposure of outer membrane protein and lipopolysaccharide epitopes in Brucella species studied by enzyme-linked immunosorbent assay and flow cytometry. Infect Immun. 1995, 63: 3945-3952.PubMed CentralPubMedGoogle Scholar
- Cloeckaert A, de Wergifosse P, Dubray G, Limet JN: Identification of seven surface-exposed Brucella outer membrane proteins by use of monoclonal antibodies: immunogold labeling for electron microscopy and enzyme-linked immunosorbent assay. Infect Immun. 1990, 58: 3980-3987.PubMed CentralPubMedGoogle Scholar
- Bowden RA, Cloeckaert A, Zygmunt MS, Dubray G: Outer-membrane protein- and rough lipopolysaccharide-specific monoclonal antibodies protect mice against Brucella ovis. J Med Microbiol. 1995, 43: 344-347. 10.1099/00222615-43-5-344.View ArticlePubMedGoogle Scholar
- Cloeckaert A, Zygmunt MS, Dubray G, Limet JN: Characterization of O-polysaccharide specific monoclonal antibodies derived from mice infected with the rough Brucella melitensis strain B115. J Gen Microbiol. 1993, 139: 1551-1556. 10.1099/00221287-139-7-1551.View ArticlePubMedGoogle Scholar
- Cloeckaert A, Jacques I, Bowden RA, Dubray GI, Limet JN: Monoclonal antibodies to Brucella rough lipopolysaccharide: characterization and evaluation of their protective effect against B. abortus. Res Microbiol. 1993, 144: 475-484. 10.1016/0923-2508(93)90055-7.View ArticlePubMedGoogle Scholar
- Grilló MJ, Manterola L, de Miguel MJ, Muñoz PM, Blasco JM, Moriyón I, López-Goñi I: Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. Vaccine. 2006, 24: 2910-2916. 10.1016/j.vaccine.2005.12.038.View ArticlePubMedGoogle Scholar
- Cloeckaert A, Jacques I, Grilló MJ, Marín CM, Grayon M, Blasco J-M, Verger J-M: Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis. Vaccine. 2004, 22: 2827-2835. 10.1016/j.vaccine.2004.01.001.View ArticlePubMedGoogle Scholar
- Martín-Martín AI, Sancho P, Tejedor C, Fernández-Lago L, Vizcaíno N: Differences in the outer membrane-related properties of the six classical Brucella species. Vet J. 2011, 189: 103-105. 10.1016/j.tvjl.2010.05.021.View ArticlePubMedGoogle Scholar
- Zygmunt MS, Jacques I, Bernardet N, Cloeckaert A: Lipopolysaccharide heterogeneity in the atypical group of novel emerging Brucella species. Clin Vaccine Immunol. 2012, 19: 1370-1373. 10.1128/CVI.00300-12.PubMed CentralView ArticlePubMedGoogle Scholar
- Vizcaíno N, Cloeckaert A: Biology and Genetics of the Brucella Outer Membrane. Brucella: Molecular Microbiology and Genomics. Edited by: López-Goñi I, O’Callaghan D. 2012, Horizon Press, Norfolk, UK, 133-161.Google Scholar
- Zaccheus MV, Ali T, Cloeckaert A, Zygmunt MS, Weintraub A, Iriarte M, Moriyón I, Widmalm G: The epitopic and structural characterization of Brucella suis biovar 2 O-polysaccharide demonstrates the existence of a new M-negative C-negative smooth Brucella serovar. PLoS One. 2013, 8: e53941-10.1371/journal.pone.0053941.PubMed CentralView ArticlePubMedGoogle Scholar
- Wattam AR, Inzana TJ, Williams KP, Mane SP, Shukla M, Almeida NF, Dickerman AW, Mason S, Moriyón I, O’Callaghan D, Whatmore AM, Sobral BW, Tiller RV, Hoffmaster AR, Frace MA, De Castro C, Molinaro A, Boyle SM, De BK, Setubal JC: Comparative genomics of early-diverging Brucella strains reveals a novel lipopolysaccharide biosynthesis pathway. MBio. 2012, 3: e00246-e00512. 10.1128/mBio.00388-12.PubMed CentralView ArticleGoogle Scholar
- Tsolis RM, Seshadri R, Santos RL, Sangari FJ, Lobo JMG, de Jong MF, Ren Q, Myers G, Brinkac LM, Nelson WC, Deboy RT, Angiuoli S, Khouri H, Dimitrov G, Robinson JR, Mulligan S, Walker RL, Elzer PE, Hassan KA, Paulsen IT: Genome degradation in Brucella ovis corresponds with narrowing of its host range and tissue tropism. PLoS One. 2009, 4: e5519-10.1371/journal.pone.0005519.PubMed CentralView ArticlePubMedGoogle Scholar
- Vizcaíno N, Caro-Hernández P, Cloeckaert A, Fernández-Lago L: DNA polymorphism in the omp25/omp31 family of Brucella spp.: identification of a 1.7-kb inversion in Brucella cetaceae and of a 15.1-kb genomic island, absent from Brucella ovis, related to the synthesis of smooth lipopolysaccharide. Microbes Infect. 2004, 6: 821-834. 10.1016/j.micinf.2004.04.009.View ArticlePubMedGoogle Scholar
- Zygmunt MS, Blasco JM, Letesson J-J, Cloeckaert A, Moriyón I: DNA polymorphism analysis of Brucella lipopolysaccharide genes reveals marked differences in O-polysaccharide biosynthetic genes between smooth and rough Brucella species and novel species-specific markers. BMC Microbiol. 2009, 9: 92-10.1186/1471-2180-9-92.PubMed CentralView ArticlePubMedGoogle Scholar
- Suarez CE, Pacheco GA, Vigliocco AM: Immunochemical studies of oligosaccharides obtained from the lipopolysaccharide of Brucella ovis. Vet Microbiol. 1990, 22: 329-334. 10.1016/0378-1135(90)90019-R.View ArticlePubMedGoogle Scholar
- Moreno E, Jones LM, Berman DT: Immunochemical characterization of rough Brucella lipopolysaccharides. Infect Immun. 1984, 43: 779-782.PubMed CentralPubMedGoogle Scholar
- Barquero-Calvo E, Chaves-Olarte E, Weiss DS, Guzmán-Verri C, Chacón-Díaz C, Rucavado A, Moriyón I, Moreno E:Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection. PLoS One. 2007, 2: e631-10.1371/journal.pone.0000631.PubMed CentralView ArticlePubMedGoogle Scholar
- Riezu-Boj JI, Moriyón I, Blasco JM, Marín CM, Diaz R: Comparison of lipopolysaccharide and outer membrane protein-lipopolysaccharide extracts in an enzyme-linked immunosorbent assay for the diagnosis of Brucella ovis infection. J Clin Microbiol. 1986, 23: 938-942.PubMed CentralPubMedGoogle Scholar
- Chacón-Díaz C, Muñoz-Rodríguez M, Barquero-Calvo E, Guzmán-Verri C, Chaves-Olarte E, Grilló MJ, Moreno E: The use of green fluorescent protein as a marker for Brucella vaccines. Vaccine. 2011, 29: 577-582. 10.1016/j.vaccine.2010.09.109.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.